Comparing two drug combos for untreated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug, zilovertamab vedotin, added to standard chemo, compared with another approved drug combo for people with untreated DLBCL (a type of lymphoma). It aims to see which is more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a specific subtype of DLBCL called germinal center B-cell (GCB) type, confirmed by biopsy.
- Your disease must be PET-positive (showing active lymphoma on a special scan), with a score of 4 or 5 on the Lugano scale.
- You must not have received any prior treatment for your DLBCL.
- If you have HIV, it must be well-controlled with antiretroviral therapy.
- If you have a history of hepatitis B or C, the virus must be undetectable with treatment.
- You cannot have certain heart conditions, ongoing infections, autoimmune diseases needing treatment in the last 2 years, or active lymphoma in the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding zilovertamab vedotin to standard chemo (R-CHP) works better than standard chemo (R-CHOP) for people with untreated diffuse large B-cell lymphoma (DLBCL). It aims to find a more effective treatment option.
This trial studies zilovertamab vedotin added to standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It may help by targeting lymphoma cells and improving how well standard treatment works after prior treatments have failed.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Hear when a new Lymphoma, Large B-Cell, Diffuse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.